Supplementary Material 4. Network graphs of each outcome. Total netgraph of (A) liver biopsy-based outcomes, (a) NAS, (b) fibrosis stage, (c) NASH resolution; (B) non-invasive technique-based outcomes, (a) liver fat content by 1H-MRS, (b) liver fat content by CAP; and (C) biological and anthropometric outcomes, (a) ALT, (b) AST, (c) HbA1c, (d) FPG, (e) HOMA-IR, (f) T-Chol, (g) LDL-C, (h) TG, (i) BMI, and (j) WC. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; FPG, fasting plasma glucose; GLP-1RA, glucagon-like peptide-1 receptor agonist; 1H-MRS, proton magnetic resonance spectroscopy; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein-cholesterol; NAFLD, nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver activity score; NASH, nonalcoholic steatohepatitis; T-Chol, total cholesterol; TG, triglyceride; TZD, thiazolidinedione; WC, waist circumference.